01977nam a2200385 a 4500001001200000003000800012006001900020007001500039008004100054010001700095020003000112020002700142020002700169040002100196035002100217050002500238082001700263100002000280245015800300260004700458300002900505490005700534490001200591504005100603505046900654533015201123650001701275650002401292655002901316710001701345830006501362830002101427856012601448999001701574ebr10681073CaPaEBRm        u        cr cn|||||||||100616s2010    nyua    sb    001 0 eng d  z  2010025523  z9781616689278 (softcover)  z1616689277 (softcover)  z9781617284809 (e-book)  aCaPaEBRcCaPaEBR  a(OCoLC)71100021914aRC848.F3bY66 2010eb04a616.3/622221 aYoneda, Masato.10aInsulin resistance and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH)h[electronic resource] /cMasato Yoneda ... [et al.].  aNew York :bNova Biomedical Books,cc2010.  aviii, 54 p. :bcol. ill.1 aMetabolic diseases--laboratory and clinical research1 aNovinka  aIncludes bibliographical references and index.0 aNAFLD and insulin resistance (IR) -- Pathophysiology of NASH : insulin resistance, free fatty acids, and cytokines -- Adiponectin and NASH -- TNF-[alpha] and NAFLD/NASH -- Leptin and NAFLD/NASH -- Peroxisome proliferators-activated receptors (PPARs) and NAFLD/NASH -- Iron overload and NAFLD/NASH -- Mitochondrial abnormalities and NAFLD/NASH -- Genetic influences in NAFLD/NASH -- Therapeutic strategy for NASH patients -- Natural history of NAFLD -- Conclusions.  aElectronic reproduction.bPalo Alto, Calif. :cebrary,d2013.nAvailable via World Wide Web.nAccess may be limited to ebrary affiliated libraries. 0aFatty liver. 0aInsulin resistance. 7aElectronic books.2local2 aebrary, Inc. 0aMetabolic diseases--laboratory and clinical research series. 0aNovinka (Series)40uhttp://site.ebrary.com/lib/rucke/Doc?id=10681073zAn electronic book accessible through the World Wide Web; click to view  c60394d60394